Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Changyanning granules for functional diarrhea and diarrhea-predominant irritable bowel syndrome
ChiCTR2000028830Phase 4Not yet recruiting
- Sponsor
- Sir Run-Run Shaw Hospital
- Start
- Jan 2020
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of Changyanning and bacillus subtilis in functional diarrhea and Diarrhea-predominant irritable bowel syndrome (IBS-D) (2 arms), sponsored by Sir Run-Run Shaw Hospital. Primary endpoint: Total effective rate. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
Changyanningbacillus subtilis
03
Conditions
functional diarrheaDiarrhea-predominant irritable bowel syndrome (IBS-D)
Beyond the preview
Go deeper on ChiCTR2000028830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000028830.